- Home
- PEGA vs ROIV Comparison
PEGA vs ROIV Comparison
Compare PEGA & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- ROIV
- Stock Information
- Founded
- PEGA 1983
- ROIV 2014
- Country
- PEGA United States
- ROIV United Kingdom
- Employees
- PEGA N/A
- ROIV N/A
- Industry
- PEGA EDP Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- PEGA Technology
- ROIV Health Care
- Exchange
- PEGA Nasdaq
- ROIV Nasdaq
- Market Cap
- PEGA 7.8B
- ROIV 8.4B
- IPO Year
- PEGA 1996
- ROIV N/A
- Fundamental
- Price
- PEGA $98.18
- ROIV $10.76
- Analyst Decision
- PEGA Buy
- ROIV Buy
- Analyst Count
- PEGA 13
- ROIV 4
- Target Price
- PEGA $100.38
- ROIV $17.50
- AVG Volume (30 Days)
- PEGA 1.0M
- ROIV 5.9M
- Earning Date
- PEGA 04-22-2025
- ROIV 05-29-2025
- Dividend Yield
- PEGA 0.12%
- ROIV N/A
- EPS Growth
- PEGA 156.48
- ROIV N/A
- EPS
- PEGA 2.14
- ROIV N/A
- Revenue
- PEGA $1,642,666,000.00
- ROIV $122,585,000.00
- Revenue This Year
- PEGA $9.61
- ROIV N/A
- Revenue Next Year
- PEGA $6.09
- ROIV N/A
- P/E Ratio
- PEGA $45.03
- ROIV N/A
- Revenue Growth
- PEGA 14.29
- ROIV 140.04
- 52 Week Low
- PEGA $55.71
- ROIV $8.73
- 52 Week High
- PEGA $113.67
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- PEGA 74.71
- ROIV 49.33
- Support Level
- PEGA $92.42
- ROIV $10.58
- Resistance Level
- PEGA $95.67
- ROIV $11.77
- Average True Range (ATR)
- PEGA 2.61
- ROIV 0.34
- MACD
- PEGA 0.75
- ROIV -0.05
- Stochastic Oscillator
- PEGA 98.02
- ROIV 15.13
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.